Global animal health biotech player Zoetis is to create between 80 and 100 jobs over the next three years in an expansion of its Tullamore manufacturing and development facility.
The expansion by Zoetis in Tullamore should significantly increase its capacity for producing veterinary monoclonal antibodies (mAbs) over time. These therapeutic biopharmaceuticals are the latest breakthroughs in animal medicine from Zoetis’ innovative pipeline of products.
“The decision of Zoetis to further extend its footprint here and expand its Tullamore facility is really fantastic news and a testament to the existing team,” said Tánaiste and Minister for Enterprise Trade and Employment Leo Varadkar, TD.
“The expansion will offer current and future employees tremendous experience and career opportunities”
“The Midlands has a wealth of talent to draw from and I wish the company the very best with this latest development.”
Concentration of biologic manufacturing
The planned expansion of the existing Zoetis facility in Tullamore will strengthen and diversify the Zoetis global manufacturing and supply network, enabling it to meet growing commercial demand and support future growth in veterinary biopharmaceuticals.
This class of therapy includes some of Zoetis’ flagship biopharmaceutical products, such as Cytopoint, Librela, and Solensia. Cytopoint, the first monoclonal antibody for use in animals, targets and neutralizes itch for dogs with allergic or atopic dermatitis, while Librela, and Solensia help alleviate osteoarthritis pain in dogs and cats, respectively.
“This site has undergone significant investment and development since 2017. In preparation for the commercial launch of Solensia, Zoetis invested in the site to scale our manufacturing process to meet demand and has grown the team accordingly,” said Conor O’Dea, Site Lead, who has managed the site for 20 years.
“With the high concentration of biologic manufacturing sites in the area and the skilled Irish workforce, we have built a strong team with extensive experience in all aspects of biopharmaceuticals manufacture, process development, Quality, Engineering and Supply Chain – and we look forward to developing it further with this investment. The expansion will offer current and future employees tremendous experience and career opportunities.”
The current Tullamore site supports development and manufacturing services across all phases of biopharmaceutical development and commercialisation, including the manufacture of Solensia. The expansion is planning, subject to approvals, to break ground in early 2022 and become fully operational by 2025.
This investment will potentially create 80-100 new jobs over the next three years, with some roles beginning to phase in later this year. Currently, Zoetis employs approximately 90 highly skilled scientists and technicians on the Tullamore site, which became part of the Zoetis network when it acquired from Nexvet Biopharma in 2017.
“Today’s announcement by Zoetis on the expansion of its Irish operation is welcome,” said IDA Ireland CEO Martin Shanahan.
“This biotech facility by the world’s leading veterinary medicines company adds another globally established name to the significant and growing cluster of biopharma companies operating in Ireland which sees substantial investment annually in Biopharma R&D by IDA client companies.
“This expansion demonstrates Zoetis’ confidence in the highly skilled and talented workforce available in the Midlands and exemplifies IDA Ireland’s continued commitment to winning jobs and investment in regional locations,” Shanahan said.